

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/785,374	
			Filing Date	February 24, 2004	
			First Named Inventor	Summar et al.	
			Art Unit	1638	
			Examiner Name	D. Johannsen	
Sheet	1	of	1	Attorney Docket Number	1242/58

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Australian Patent Office Examination Report dated November 2, 2007 for Australian Patent Application No. 2005216270.	
	2	Communication pursuant to Article 96(2) EPC corresponding to European Application No. 05 723 789.3 - 2123 dated September 14, 2007.	
	3	Boger et al. "Is asymmetric dimethylarginine a novel mark of atherosclerosis?" <u>Circulation</u> , 101(14): 160-161 (April 11, 2000). (ABSTRACT)	
	4	Maxwell et al. "Endothelial dysfunction in hypercholesterolemia is reserved by a nutritional product designed to enhance nitric oxide activity," <u>Cardiovasc Drugs Ther</u> , 14(3): 309-316 (June 2000). (ABSTRACT)	
	5	Maxwell et al. "Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar," <u>Vasc Med</u> , 5(1): 11-19 (2000). (ABSTRACT).	
	6	Vosatka, "Persistent pulmonary hypertension of the newborn," <u>N Engl J Med</u> , 346(11): 864 (March 14, 2002).	
	7	Alves et al. "The SGOT/SGPT rataio in alcoholic liver disease," <u>Acta Med Port</u> , Vol. 3, pgs. 255-260 (1981).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.